Penserra Capital Management LLC bought a new stake in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 776,002 shares of the company's stock, valued at approximately $11,702,000. Penserra Capital Management LLC owned approximately 2.84% of Abrdn Life Sciences Investors as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kapstone Financial Advisors LLC bought a new position in shares of Abrdn Life Sciences Investors in the third quarter worth $177,000. Ashton Thomas Securities LLC bought a new position in Abrdn Life Sciences Investors in the 3rd quarter worth about $148,000. Stephens Inc. AR raised its holdings in shares of Abrdn Life Sciences Investors by 7.6% in the 3rd quarter. Stephens Inc. AR now owns 12,707 shares of the company's stock valued at $192,000 after acquiring an additional 896 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Abrdn Life Sciences Investors during the 3rd quarter valued at about $204,000. Finally, Future Financial Wealth Managment LLC purchased a new position in shares of Abrdn Life Sciences Investors during the third quarter worth about $30,000. 32.21% of the stock is currently owned by institutional investors.
Abrdn Life Sciences Investors Trading Down 0.3 %
Abrdn Life Sciences Investors stock traded down $0.04 during mid-day trading on Friday, hitting $13.79. 116,697 shares of the company traded hands, compared to its average volume of 74,251. The stock has a fifty day moving average price of $14.90 and a 200-day moving average price of $14.68. Abrdn Life Sciences Investors has a one year low of $11.62 and a one year high of $15.90.
Abrdn Life Sciences Investors Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 10th. Stockholders of record on Thursday, November 21st will be issued a dividend of $0.50 per share. This is an increase from Abrdn Life Sciences Investors's previous quarterly dividend of $0.49. This represents a $2.00 dividend on an annualized basis and a dividend yield of 14.50%. The ex-dividend date of this dividend is Thursday, November 21st.
About Abrdn Life Sciences Investors
(
Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Featured Stories
Before you consider Abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abrdn Life Sciences Investors wasn't on the list.
While Abrdn Life Sciences Investors currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
